Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now

ImmunoGen Stock Jumps Following Ovarian Cancer Study Results

Published Dec 01, 2021 00:04
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters.
 
IMGN
0.00%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Sam Boughedda

Investing.com — ImmunoGen Inc (NASDAQ:IMGN) stock jumped at the open today after it announced positive results from its trial of mirvetuximab soravtansine in ovarian cancer.

Notably, the SORAYA trial met its primary endpoint with a confirmed objective response rate of 32.4%.

ImmunoGen shares are currently up over 37%.

The company said it aims to complete the Biologics License Application for mirvetuximab, its potential treatment for patients with platinum-resistant ovarian cancer, by submitting an application to the Food and Drug Administration for accelerated approval in the first quarter of 2022.

Mark Enyedy, ImmunoGen's president and CEO, said it is an "exciting moment, both for the field of ovarian cancer and for ImmunoGen," with the outcomes from the SORAYA trial "further validate our longstanding history of innovation in ADCs." 

"Commercial preparations are well underway to support the potential launch of mirvetuximab next year," he added.

 

ImmunoGen Stock Jumps Following Ovarian Cancer Study Results
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email